

TherapeuticsMD, Inc.
Form 3
December 15, 2014

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â Donegan Michael C		(Month/Day/Year)	TherapeuticsMD, Inc. [TXMD]	
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
6800 BROKEN SOUND			(Check all applicable)	
PARKWAY NW,Â THIRD			_____ Director _____ 10% Owner	
FLOOR			<input checked="" type="checkbox"/> Officer _____ Other	
(Street)			(give title below) (specify below)	
			Vice President Finance	
BOCA			6. Individual or Joint/Group Filing(Check Applicable Line)	
RATON,Â FLÂ 33487-3507			<input checked="" type="checkbox"/> Form filed by One Reporting Person	
(City)	(State)	(Zip)	_____ Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of	

Edgar Filing: TherapeuticsMD, Inc. - Form 3

				Shares		or Indirect (I) (Instr. 5)	
Non-qualified stock option	06/21/2014 ⁽¹⁾	06/20/2023	Common Stock	75,000	\$ 2.98	D	Â
Non-qualified stock option	07/09/2015 ⁽²⁾	07/08/2024	Common Stock	50,000	\$ 5.01	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Donegan Michael C 6800 BROKEN SOUND PARKWAY NW THIRD FLOOR BOCA RATON, FL 33487-3507	Â	Â	Â Vice President Finance	Â

Signatures

/s/ Michael C.
Donegan

12/15/2014

**Signature of
Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The 75,000 shares underlying this option vest at the rate of 25,000 shares on the first, second and third anniversary of the date of grant of 6/21/13.
- (2) The 50,000 shares underlying this option vest at the rate of 12,500 shares on the first, second, third and fourth anniversary of the date of grant of 7/9/14.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.